Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
about
Chronic myeloid leukemia: reminiscences and dreamsCurrent status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemiaTyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia: Long-Term Patient Care and ManagementPhosphorylation of Dok1 by Abl family kinases inhibits CrkI transforming activity.Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trLong-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis.Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia.Selecting the best frontline treatment in chronic myeloid leukemiaTriplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous LeukemiaMolecular response in CML: where is the bar?Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended.The choice of first-line chronic myelogenous leukemia treatment.Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.Milestones and monitoring.Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR TechniquesChronic-phase chronic myeloid leukemia: Not always a reassuring diagnosis.Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study.Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib.A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.Combination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients.The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaAnalysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International Scale.Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsDevelopment and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale.The predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real-world medical centre in a developing country.Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies.Achieving early molecular response in chronic myeloid leukemia in chronic phase to reduce the risk of progression: clinical relevance of the 3- and 6-month time points.Analyzing molecular response in chronic myeloid leukemia clinical trials: pitfalls and golden rules.Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission.Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.
P2860
Q26748769-095A0783-9C03-4695-9521-B09E9056813FQ27027369-9C6E9A72-7AFB-41FC-8430-548B1764D073Q28075963-0FCC72A2-2052-43C1-84F3-8EA34F34CC89Q30009346-94444F86-BC22-4D71-8118-7C6CA70956ABQ30242015-D5C3766B-981F-4046-8D03-E7ED7C99D379Q31033077-F69D08C7-B898-4B3C-9EBC-7F1448095605Q33434675-ABBFCE84-05ED-4880-834B-1F6ED5C8686EQ33439536-DE61ADF3-E3F8-4A39-AD05-1646219C0DC1Q33593877-EAD4E985-086C-4B8B-A296-B87450C5E4C0Q33701852-A65AD4B1-7A07-484F-BD86-2175F8B50B85Q33764253-B7CBF981-D8B0-4A64-94DB-B731D8E4D6C0Q33787355-F6776BAF-4746-41B0-BE67-4A4F984BFD62Q33806617-2944F180-0111-4599-8B02-8BB8302699B2Q33948671-20FCB96A-B658-46D6-8600-F048C3CC05EBQ34155213-CEE3F7D8-BE3B-4AB0-BDF3-097E0ABAC519Q35221071-863C66CD-19DC-4FAC-8091-ABE89F739477Q35560018-E02CA975-F528-487C-A029-511CD5D86D7CQ35652844-9FCA69A8-067B-46E6-844E-6E429C1E6A4AQ35674595-9CDA7D3B-7942-4D19-BFD1-BB11AA64927AQ35925580-65DB623C-5AF9-49C6-8412-40D7C3EED9BFQ35928884-AC0DA8D9-5CB7-4530-8157-C10DBE638401Q36104098-602101D5-69C9-4588-AA3C-1D5F183C5E7EQ36237327-D1184402-58E3-4B15-B1B7-AFCFD7038EA0Q36302377-87075657-205F-4137-983D-E14A7531E53DQ36442499-7DE6872A-B57F-43E0-92A2-2442CF5FFE98Q36478229-A4985209-BBF5-4AA2-A01E-43C870D12593Q36547224-750666B4-95A2-46B6-A1A1-12D908FDB548Q36734508-26902F45-C0C1-41E9-AFD9-9758E164A29EQ36894983-81FD7CA2-5F84-4DF0-8DCE-F2B34459BDCEQ37103050-10DC95A4-C45F-4513-B384-B34719B5E2D4Q37509428-F064242C-A38E-43F6-B0DE-6DBF8C183458Q37588786-C6A1F2C8-4A6F-46BF-908F-F544E3F1CDE5Q37714627-77836104-6268-459C-9017-D0BA446777A7Q38199143-7ABC3C71-4DF6-469B-8A45-CBF543DD9019Q38202913-79C5E59A-1BEE-40DC-950D-ABDDC3C6D228Q38254385-E6AD7A01-159E-4AD1-84A3-CE069A36B291Q38262877-A2AA5DAE-5413-4C07-9943-20EF74F4E92FQ38269617-376D50E4-B3E3-4900-BC59-889B2F019062Q38363058-A58DE21C-A797-4F4D-86F8-5318FF400FCAQ38389475-23A3B690-D110-4A76-B886-F87CF6049938
P2860
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Early molecular response predi ...... rontline nilotinib or imatinib
@ast
Early molecular response predi ...... rontline nilotinib or imatinib
@en
type
label
Early molecular response predi ...... rontline nilotinib or imatinib
@ast
Early molecular response predi ...... rontline nilotinib or imatinib
@en
prefLabel
Early molecular response predi ...... rontline nilotinib or imatinib
@ast
Early molecular response predi ...... rontline nilotinib or imatinib
@en
P2093
P2860
P50
P1433
P1476
Early molecular response predi ...... rontline nilotinib or imatinib
@en
P2093
Carmino Antonio De Souza
Chiaki Nakaseko
Dietger Niederwieser
Hans D Menssen
Matt E Kalaycio
Stephan Meier
Timothy P Hughes
Xiaolin Fan
P2860
P304
P356
10.1182/BLOOD-2013-06-510396
P407
P50
P577
2013-12-11T00:00:00Z